-
公开(公告)号:HRP20190509T1
公开(公告)日:2019-05-03
申请号:HRP20190509
申请日:2019-03-14
Applicant: UBE INDUSTRIES
Inventor: IWAMURA RYO , TANAKA MASAYUKI , KATSUBE TETSUSHI , SHIGETOMI MANABU , OKANARI EIJI , TOKUNAGA YASUNORI , FUJIWARA HIROSHI
IPC: C07D213/74 , A61K31/4439 , A61K31/444 , A61K31/501 , A61K31/506 , A61P11/00 , A61P11/06 , A61P19/00 , A61P43/00 , C07D401/14 , C07D405/14 , C07D409/14 , C07D417/12 , C07D417/14
-
公开(公告)号:CA2637388C
公开(公告)日:2013-12-17
申请号:CA2637388
申请日:2007-01-16
Applicant: UBE INDUSTRIES
Inventor: HAGIHARA MASAHIKO , TANAKA MASAYUKI , KATSUBE TETSUSHI , OKUDO MAKOTO , IWASE NORIAKI , SHIGETOMI MANABU , KANDA TOMOKO , NAKANISHI TAKAYUKI
IPC: C07D487/04 , A61K31/5025 , A61P1/00 , A61P1/18 , A61P9/00 , A61P11/00 , A61P13/12 , A61P29/00 , A61P31/00 , A61P43/00
Abstract: Disclosed is a pyrrolopyridazinone compound represented by the general formula (1) below or a pharmacologically acceptable salt thereof. (1) In the formula, R1 represents an alkyl group or the like; R2 represents a cycloalkyl group or the like; R3 represents a hydrogen atom or the like; and R4 represents a hydrogen atom, a halogen atom or the like.
-
公开(公告)号:CA2785668A1
公开(公告)日:2011-06-30
申请号:CA2785668
申请日:2010-12-24
Applicant: UBE INDUSTRIES
Inventor: IWAMURA RYO , TANAKA MASAYUKI , KATSUBE TETSUSHI , SHIBAKAWA NOBUHIKO , SHIGETOMI MANABU , OKANARI EIJI , KANDA TOMOKO , TOKUNAGA YASUNORI , FUJIWARA HIROSHI
IPC: C07D213/74 , A61K31/44 , A61K31/4427 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61P11/00 , A61P11/06 , A61P11/08 , A61P27/06 , A61P43/00 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12
Abstract: A compound represented by general formula (I) or a pharmacologically acceptable salt thereof, a medicinal composition comprising the same, and a medicinal composition for the treatment or prevention of respiratory diseases or glaucoma.
-
公开(公告)号:CA2637388A1
公开(公告)日:2007-07-19
申请号:CA2637388
申请日:2007-01-16
Applicant: UBE INDUSTRIES
Inventor: HAGIHARA MASAHIKO , NAKANISHI TAKAYUKI , TANAKA MASAYUKI , IWASE NORIAKI , KATSUBE TETSUSHI , OKUDO MAKOTO , SHIGETOMI MANABU , KANADA TOMOKO
IPC: C07D487/04 , A61K31/5025 , A61P1/00 , A61P1/18 , A61P9/00 , A61P11/00 , A61P13/12 , A61P29/00 , A61P31/00 , A61P43/00
Abstract: The present invention discloses a pyrrolopyridazinone compound represented by the formula (1): wherein R 1 represents C 1 -C 2 alkyl group or halogeno C 1 -C 2 alkyl group, R 2 repersents C 3 -C 5 cycloalkyl group, (C 3 -C 5 cycloalkyl)C 1 -C 2 alkyl group or C 1 -C 3 alkyl group, R 3 represents hydrogen atom, or methylene group or cis-vinylene group for forming substituted oxygen-containing hetero ring in combination with group -O-R 2 , R 4 represents hydrogen atom, halogen atom, C 1 -C 8 alkyl group, C 2 -C 6 alkenyl group, C 2 -C 6 alkynyl group, hydroxy C 3 -C 6 alkenyl group, hydroxy C 3 -C 6 alkynyl group, C 1 -C 6 alkyl group substituted by substituent(s) selected from Substituent group (a), C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), "C 1 -C 3 alkyl group which is substituted by C 3 -C 6 cycloalkyl group which may be substituted by substituent(s) selected from Substituent group (b), and which may be substituted by a hydroxy group", an aromatic ring group or heteroaromatic ring group each of which may be substituted by a substituent(s) selected from Substituent group (c) or "C 1 -C 2 alkyl group which is substituted by aromatic ring group or heteroaromatic ring group each of which may be substituted by group(s) selected from Substituent group (c), and which may be substituted by a hydroxy group", Substituent group (a) represents a halogen atom, hydroxy group, cyano group, carboxy group, C 1 -C 5 alkoxy group, halogeno C 1 -C 4 alkoxy group, C 3 -C 6 cycloalkoxy group, (C 3 -C 6 cycloalkyl) C 1 -C 2 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyl group, C 2 -C 4 alkanoyloxy group or C 1 -C 4 alkyl-substituted amino group, Substituent group (b) represents a hydroxy group or a halogen atom, Substituent group (c) represents a halogen atom, a hydroxy group, a cyano group, a nitro group, a carboxy group, C 1 -C 5 alkoxy group, C 1 -C 4 alkoxycarbonyl group, C 2 -C 4 alkanoyloxy group, C 1 -C 4 alkyl-substituted amino group or a C 1 -C 4 alkyl group which may be substituted by a substituent(s) selected from the group consisting of (a halogen atom, a hydroxy group and a carboxy group), or a pharmaceutically acceptable salt thereof.
-
公开(公告)号:CZ20033519A3
公开(公告)日:2004-06-16
申请号:CZ20033519
申请日:2002-06-27
Applicant: UBE INDUSTRIES
Inventor: KUROKI YOSHIAKI , UENO HITOSHI , KATSUBE TETSUSHI , KAWAGUCHI TETSUO , OKANARI EIJI , TANAKA ICHIRO , TANAKA MASAYUKI , HAGIHARA MASAHIKO
IPC: A61P11/06 , A61P29/00 , A61P37/08 , A61P43/00 , C07D215/12 , C07D215/18 , C07D215/14 , A61K31/47
Abstract: Dibenzocycloheptene derivatives (I) are new. Dibenzocycloheptene derivatives of formula (I) and their salts are new. [Image] R1H, halo, OH, NO2, CN, CONH2, CHO, COOH, 1H-tetrazol-5-yl, Alk1, 1-4C hydroxyalkyl, 2-4C alkenyl, 2-4C alkynyl, S(O)bAlk or OAlk1; Alk : 1-4C alkyl; Alk1Alk or 1-4C fluoroalkoxy; R2H, halo, NO2, CN, Alk or OAlk; A : 5- or 6-membered optionally benzofused aromatic heterocyclyl containing 1-3 O, S or N and optionally substituted by halo, NO2, CN, Alk1, OAlk1, SAlk or 3 or 4C alkylene; B : CH=CH, CH2O, CH2CH2, CH2S, OCH2 or SCH2; X : O, S, CH2 or =CH; Y : 1-10C alkylene (optionally substituted by halo, Alk or OAlk) or a group of formula (i); b, o, p : 0-2; Z : optionally protected carboxyl, 1H-tetrazol-5-yl, NHSO2R3 or CONHSO2R3; R3Alk1 or phenyl (optionally substituted by halo, Alk1, OAlk1, NO2 or CN); m : 1-4, and n : 1-3. [Image] ACTIVITY : Antiasthmatic; Antiallergic; Antiinflammatory. In tests on guinea pigs, [3-[(E)-2-(6,7-difluoroquinolin-2-yl)ethenyl]-5H-dibenzo[a,d]cyclohepten-5-yl]oxyacetic acid (Ia) in an amount of 0.70 mu g/kg orally inhibited leukotriene D4 induced bronchoconstriction. MECHANISM OF ACTION : Leukotriene-D4 antagonist; Leukotriene-C4 antagonist; Leukotriene-E4 antagonist.
-
公开(公告)号:CA2452105A1
公开(公告)日:2003-01-09
申请号:CA2452105
申请日:2002-06-27
Applicant: UBE INDUSTRIES
Inventor: KAWAGUCHI TETSUO , KUROKI YOSHIAKI , KATSUBE TETSUSHI , UENO HITOSHI , HAGIHARA MASAHIKO , OKANARI EIJI , TANAKA ICHIRO , TANAKA MASAYUKI
IPC: A61P11/06 , A61P29/00 , A61P37/08 , A61P43/00 , C07D215/12 , C07D215/18 , C07D215/14 , A61K31/47
Abstract: A dibenzocycloheptene compound represented by the general formula (I): (I) (wherein R1 represents hydrogen, halogeno, etc.; R2 represents hydrogen, halogeno, etc.; A represents, e.g., a 5- or 6-membered heterocyclic aromatic group containing one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, the heterocyclic aromatic group optionally having halogeno, nitro, etc. as a substituent; B represents -CH=CH-, -CH2O-, etc.; Y represents C1-10 alkylene optionally having halogeno, etc. as a substituent; Z represents optionally protected carboxyl, etc.; m is an integ er of 1 to 4; n is an integer of 1 to 3; and ~~ indicates a single bond or doub le bond) or a pharmacologically acceptable salt of the compound; and a medicina l composition which contains the compound or salt as the active ingredient. Th e composition has not only strong leucotriene D4 antagonism but leucotriene C4 antagonism and leucotriene E4 antagonism. It is useful as an antasthmatic, antiallergic, or antiphlogistic.
-
公开(公告)号:CA2297815A1
公开(公告)日:1999-02-11
申请号:CA2297815
申请日:1998-07-31
Applicant: UBE INDUSTRIES
Inventor: UENO HITOSHI , KUROKI YOSHIAKI , TAKATA KATSUNORI , TANAKA MASAYUKI , BABA KOUSUKE , MOTOYAMA TAKAHIRO
IPC: C07D471/04 , C07D491/04 , C07D495/04 , C07D498/04 , C07D513/04 , C07D495/18 , C07D513/18
Abstract: N-Acylamino acid amide compounds represented by general formula (I), wherein A represents general formula (a-1) or (a-2), and B represents general formula (b) (wherein the symbols are each as defined in the description) or pharmacologically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and are useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.
-
公开(公告)号:SI2264009T1
公开(公告)日:2019-05-31
申请号:SI200931953
申请日:2009-03-12
Applicant: UBE INDUSTRIES
Inventor: IWAMURA RYO , TANAKA MASAYUKI , KATSUBE TETSUSHI , SHIGETOMI MANABU , OKANARI EIJI , TOKUNAGA YASUNORI , FUJIWARA HIROSHI
IPC: C07D213/00 , A61K31/00 , A61P11/00 , A61P19/00 , A61P43/00 , C07D401/00 , C07D405/00 , C07D409/00 , C07D417/00
-
公开(公告)号:AU2015337607A1
公开(公告)日:2017-05-25
申请号:AU2015337607
申请日:2015-10-30
Applicant: UBE INDUSTRIES
Inventor: AGA YASUHIRO , USHIYAMA SHIGERU , IWASE NORIAKI , KONO SHIGEYUKI , SUNAMOTO HIDETOSHI , MATSUSHITA TAKASHI , OGI SAYAKA , TANAKA MASAYUKI , MATOYAMA MASAAKI , UMEZAKI SATOSHI , SHIRAISHI YUSUKE , ONUMA KAZUHIRO , KOJIMA MASAHIRO , NISHIYAMA HAYATO , KIMURA TOMIO
Abstract: A compound represented by general formula (I) [in the formula, L
-
公开(公告)号:ES2383969T3
公开(公告)日:2012-06-27
申请号:ES07706860
申请日:2007-01-16
Applicant: UBE INDUSTRIES
Inventor: HAGIHARA MASAHIKO , TANAKA MASAYUKI , KATSUBE TETSUSHI , OKUDO MAKOTO , IWASE NORIAKI , SHIGETOMI MANABU , KANDA TOMOKO , NAKANISHI TAKAYUKI
IPC: C07D487/04 , A61K31/5025 , A61P1/00 , A61P1/18 , A61P9/00 , A61P11/00 , A61P13/12 , A61P29/00 , A61P31/00 , A61P43/00
Abstract: Un compuesto de pirrolopiridazinona representado por la fórmula (1):en la queR2 representa un grupo alquilo C1-C2 o un grupo halo-alquilo C1-C2,R2 representa un grupo cicloalquilo C3-C5, un grupo (cicloalquilo C3-C5)-alquilo C1-C2 o un grupo alquilo C1-C3,R3 representa un átomo de hidrógeno, o un grupo metileno o un grupo cis-vinileno, cada uno de los cuales es un grupopara la constitución de un anillo heterocíclico que contiene oxígeno sustituido junto con un grupo -O-R2,R4 representa un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C1-C8, un grupo alquenilo C2-C6, ungrupo alquinilo C2-C6, un grupo hidroxi-alquenilo C3-C6, un grupo hidroxi-alquinilo C3-C6, un grupo alquilo C1-C6sustituido con un sustituyente o sustituyentes seleccionados entre el Grupo de sustituyentes (a), un grupo cicloalquiloC1-C6, que puede estar sustituido con un sustituyente o sustituyentes seleccionados entre el Grupo de Sustituyentes(b), "un grupo alquilo C1-C3 que está sustituido con un grupo cicloalquilo C3-C6, que puede estar sustituido con unsustituyente o sustituyentes seleccionados entre el Grupo de Sustituyentes (b), y que puede estar sustituido con ungrupo hidroxi", un grupo de anillo aromático o un grupo de anillo heteroaromático, pudiendo estar cada uno de loscuales sustituido con un sustituyente o sustituyentes seleccionados entre el Grupo de Sustituyentes (c), o "un grupoalquilo C1-C2 que está sustituido con un grupo de anillo aromático o un grupo de anillo heteroaromático, estando cadauno de los cuales sustituido con un sustituyente o sustituyentes seleccionados entre el Grupo de Sustituyentes (c), yque puede estar sustituido con un grupo hidroxi",El Grupo de sustituyentes (a) representa un átomo de halógeno, un grupo hidroxi , un grupo ciano, un grupo carboxi, ungrupo alcoxi C1-C5, un grupo halo-alcoxi C1-C4, un grupo cicloalcoxi C3-C6, un grupo (cicloalquil C3-C6)alcoxi C1-C2, ungrupo alcoxicarbonilo C1-C4, un grupo alcanoílo C2-C4, un grupo alcanoiloxi C2-C4 o un grupo amino sustituido conalquilo C1-C4, el Grupo de Sustituyentes (b) representa un grupo hidroxi o un átomo de halógeno,el Grupo de Sustituyentes (c) representa un átomo de halógeno, un grupo hidroxi, un grupo ciano, un grupo nitro, ungrupo carboxi, un grupo alcoxi C1-C5, un grupo alcoxicarbonilo C1-C4, un grupo alcanoiloxi C2-C4, un grupo aminosustituido con alquilo C1-C4 o un grupo alquilo C1-C4, que puede estar sustituido con un sustituyente o sustituyentesseleccionados entre el grupo que consiste en (un átomo de halógeno, un grupo hidroxi y un grupo carboxi), o una salfarmacéuticamente aceptable de los cuales.
-
-
-
-
-
-
-
-
-